BioSpace News Archive

Scipher Medicine, developer of a molecular technology platform that can predict if a patient will actually respond to a particular drug therapy announced today that it has completed its Series A round led by Khosla Ventures.

Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that it has closed on the transaction with Sandoz to acquire the largest sterile manufacturing facility for injectable medicines in Canada, as part of a continuing expansion of its global footprint.

Boston Scientific Corporation will participate in the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 in New York City.

Diagnosed at age 45 with chronic obstructive pulmonary disease (COPD), Russell Winwood, an accomplished triathlete and Ironman doesn’t let limited lung function hold him back. He and Amanda Maucere, RDN, dietitian at Lung Health Institute, are taking the stage at an American Lung Association LUNG FORCE Expo to shed light on a trend reshaping the way chronic lung disease is managed.

National experts to discuss a new approach to ending child abuse and neglect

Texas-based INtuitive Health has announced its partnership with Presbyterian Healthcare Services, a national leader in innovative integrated health systems, to bring a new venue of care - 24/7 combined emergency and urgent care clinics - to New Mexico.

Dog lovers know too well the heartbreak of helplessly standing by as their beloved, four-legged friends endure agonizing osteoarthritis (OA). But an encouraging new study strongly suggests significant osteoarthritis relief for dogs is now available from a medical technology originally developed for humans

CORRECTION...by LabConnect, LLC

Global life sciences consulting firm Trinity Partners today announced it has acquired TGaS Advisors, the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry.

Quantum Leap Healthcare Collaborative™ (QLHC) announced today that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL™ includes the study of olaparib and durvalumab, two agents from AstraZeneca.